What is the first-line antibiotic for acute bacterial rhinosinusitis in adults without penicillin allergy?

Study for APEA Management EENT Test with flashcards and multiple choice questions, each question has hints and explanations. Get ready for your exam!

Multiple Choice

What is the first-line antibiotic for acute bacterial rhinosinusitis in adults without penicillin allergy?

Explanation:
High-dose amoxicillin-clavulanate is chosen first because it reliably covers the usual bacteria that cause acute bacterial rhinosinusitis and counters beta-lactamase–producing strains. The clavulanate component blocks that resistance mechanism, expanding activity against Haemophilus influenzae and Moraxella catarrhalis, as well as susceptible Streptococcus pneumoniae. This makes it more effective in the typical adult patient without penicillin allergy than amoxicillin alone or many alternatives. Doxycycline can be used if penicillin allergy is present, but isn’t preferred in nonallergic patients due to variability in coverage and resistance. Azithromycin has higher resistance and weaker pneumococcal activity, and cefdinir has less robust evidence guiding its use as first-line.

High-dose amoxicillin-clavulanate is chosen first because it reliably covers the usual bacteria that cause acute bacterial rhinosinusitis and counters beta-lactamase–producing strains. The clavulanate component blocks that resistance mechanism, expanding activity against Haemophilus influenzae and Moraxella catarrhalis, as well as susceptible Streptococcus pneumoniae. This makes it more effective in the typical adult patient without penicillin allergy than amoxicillin alone or many alternatives. Doxycycline can be used if penicillin allergy is present, but isn’t preferred in nonallergic patients due to variability in coverage and resistance. Azithromycin has higher resistance and weaker pneumococcal activity, and cefdinir has less robust evidence guiding its use as first-line.

Subscribe

Get the latest from Examzify

You can unsubscribe at any time. Read our privacy policy